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A B S T R A C T
Multiple randomized trials over the last decade for both symptomatic and asymptomatic carotid stenosis have proven
the efficacy of carotid endarterectomy (CEA) in reducing the risk of stroke. The aim of this prospective non-randomizing
cohort study was to determine the incidence of carotid arteries restenosis after CEA as well as to ascertain the clinical
and etiological characteristics for the development of restenosis. Treatment data from 178 KBC Rijeka patients that had
undergone CEA in the period 1. 09. 2005–30. 8. 2009 has been processed. All patients are monitored trough our Neuro-
sonology laboratory algorythm – first Doppler ultrasound examination within the first week after CEA and the following
after 1, 3, 6 and 12 months. After this time once a years. The average monitoring time was 21 month (1–36 months). In
the stated period 27 restenosis was diagnosed (15.16%). Only four of them were symptomatic (14.81%). Patient survival
rate is 98% in the first 12 and 92% in the first 36 months. Carotid restenosis is usually asymptomatic. Non-invasive post-
operative carotid arteries color Doppler screening is essential in the early identification of patients with the risk for the
development of restenosis.
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Introduction
Cerebrovascular diseases are one of the leading cau-
ses of death in industrial countries but stroke is still a
preventable disease. Internal carotid artery stenosis is
responsible for a considerable proportion of transient
ischemic attacks and strokes. Atherosclerosis is responsi-
ble for stenosis formation of extracranial carotid stenosis
and also a significant factor in restenosis after endarte-
rectomy. Carotid endarterectomy (CEA) is an effective
operation designed to prevent stroke. Multiple random-
ized trials over the last decade for both symptomatic and
asymptomatic carotid stenosis have proven the efficacy
of CEA in reducing the risk of stroke1–4.
CEA was highly beneficial for patients with 70% or
more stenosis without near-occlusion, of some benefit for
those with 50–69% stenosis, of no benefit in those with
30–49% stenosis and harmful in patients with less than
30% stenosis5. In the largest trial of asymptomatic sub-
jects Asymptomatic Carotid Surgery Trial (ACST), the
perioperative risk of stroke or death was 3.1%, and there-
after the 5-year stroke risk was 3.8 vs. 11% for best medi-
cal therapy, i.e. 16 CEA were needed to prevent one
stroke in 5 years. In the Asymptomatic Carotid Athero-
sclerosis Study (ACAS), the perioperative risk of stroke
and death was very low, and 83 CEA were needed to pre-
vent one stroke in 2 years4,6.
Recurrent carotid stenosis or restenosis is the re-nar-
rowing of the blood vessel after surgical or endovascular
revascularization. Stoney and String7 described two pa-
thologically different types of recurrent carotid stenosis;
early restenosis that results from myointimal (neointi-
mal) hyperplasia and late restenosis that results from re-
current atherosclerosis7–9. Early restenosis usually oc-
curs after 30 days but before 2 years postoperatively,
while late restenosis can be seen 2 years after the opera-
tion. Additionally, residual stenosis due to technical fail-
ure can cause “restenosis” as well, which can be observed
even earlier than 30 days postoperatively. Neointimal hy-
perplasia appears as smooth, firmly localized thickenings
at the site of previous CEA, whereas atherosclerotic le-
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sions tend to be irregular, friable, and occasionally ulcer-
ated with a tendency to give rise to symptoms in the ca-
rotid territory9. Late restenotic lesions contain foam
cells, cholesterol deposits, abundant collagen and cal-
cium just like the primary atherosclerotic lesion10. Car-
diovascular risk factors are the same as the ones for
restenosis and include smoking, family history of cardio-
vascular disease, diabetes mellitus, coronary heart dis-
ease and hyperlipidemia22,23,26,27. It has recently been
shown that newly aquired risk factors after folow-up in-
cluding hypertension, coronary heart disease, diabetes
and preipheral artery disease result in a higher risk for
restenosis after CEA. This finding underlines the impor-
tance of risk factor menagement in vascular patients in
order to reduce restenosis rates20.
Depending on the definition criteria for recurrent ca-
rotid stenosis, the length of the follow-up period, and the
deviation in the number of patients assigned to these
studies, the incidence of restenosis varied widely be-
tween 1% and 36%7,11–13. According to a review by Fre-
rick et al, the risk of recurrent carotid stenosis was 10%
in the first year, 3% in the second year, and 2% thereafter
suggesting, that most of these complications occur in the
first postoperative year14,22. Restenotic lesions are usu-
ally less thrombogenic than the primary atherosclerotic
plaques, with consequently lower risk of cerebrovascular
incidents. While primary atherosclerosis often leads to
neurological symptoms as an amaurosis fugax, transient
ischemic attack or stroke, restenosis generally appears
asymptomatic15. When restenosis became significant, re-
intervention may also become necessary to avoid the re-
occurrence of clinical symptoms. Nowadays, most of the
carotid restenotic cases are to be treated by CAS (Carotid
artery stenting) instead of a redo CEA16–18.
Patients and Methods
Treatment data from 178 KBC Rijeka patients that
had undergone CEA in the period 1. 09. 2005–30. 8. 2009
has been processed. Pre-operative work-up, clinical as
well as haemodynamic postoperative follow up has been
done in the Cerebrovascular Department and in the
Neurosonology Laboratory of the Neurology Clinic, Rije-
ka University Hospital, Croatia. ALOCA ALFA 10 ultra-
sound machine and 5–7.5 MHz transducers were used.
All patients are monitored trough our Neurosonology
Laboratory alghorithm – first doppler ultrasound exami-
nation within the first week after CEA and the following
after 1.6 and 12 months. After this time once a years.
The average monitoring time was 21 month (1–36
months). Duplex grading of ICA stenosis was according
to previously published criteria19,21,22,25. Peak systolic ve-
locities (PSV) within the ICA of 150 to 249 mm/sec and
the ratio of PSV of the ICA and common carotid artery
(CCA) of 2.0 to 3.9 were quantified as 50 to 69% stenosis.
PSV within the ICA greater 250 mm/sec and the ratio of
PSV of the ICA and CCA of greater 4 were quantified as
70 to 99% stenosis. In our study carotid restenosis was
defined as an above 50% restenosis or occlusion. Digital
subtraction carotidography (DSA) or MSCT carotido-
graphy was performed in every patient prior to the CEA.
Also we perform to all patients CT scan or brain MRI.
Incidences of risk factors for arterial stenosis such as
treated hypertension, smoking,treated diabetes, hyper-
cholesterolemia and hyperhomocisteinemia in these two
groups were also monitored.
Results
This study focused on the incidence of carotid artery
restenosis based on Duplex studies and confirmed by
angiography. In the stated period 27 restenosis of 178
CEA was diagnosed (15.16%). The average monitoring
time was 21 month (1–36 months. Patient baseline demo-
graphic and distribution of risk factors amoung the stud-
ied patients with carotid restenosis are shown in Table 1.
There was no statistical difference between the tradi-
tional cardiovascular risk factors between carotid steno-
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Fig. 1. Carotid restenosis.
sis patients after CEA and those patients who developed
carotid restenosis, except for overweight patients with
increased BMI p<0.05. Eighteen patients (66.67%) with
restenosis were treated by endovascular procedures –
stenting. Considering all restenosis, only four were sym-
ptomatic (14.81%) while five were post-operative oclu-
sions (18.52%). Two oclusions occured within the first
week after CEA. Patient survival rate is 98% in the first
12 and 92% in the first 36 months. Over 55.6% of reste-
nosis developed within six months follow-up, 77,8% wi-
thin 18 months (Figure 1).
All recognized restenosis were in group of early reste-
nosis.
Discussion and Conclusion
Carotid stenosis or/and its consequencies could be
prevented. Since the main risk factors for atherosclerosis
are well known, prevention can be achieved by lipid-low-
ering, antihypertensive, antidiabetic therapies, weight
control or by omitting smoking and treating other risk
factors. Besides these modifiable factors, some risk fac-
tors like age, gender or gene polymorphisms cannot be
affected. In contrast, the prevention of recurrent steno-
sis is not yet fully established. It is probably useful to pay
further attention to the classical atherosclerosis risk fac-
tors but most important prevention methods is regular
ultrasonographic checkup of the carotids – 1 week, 1
months, 3 months, 6 months, 12 months postoperatively,
than every 12 months thereafter, should be scheduled re-
garding, that the incidence of restenosis is highest within
the first 18 months after CEA. Routine follow – up and
serial monitoring of all patients with carotid after CEA is
required, especially in first 18 months because restenosis
usually arises early on after surgery and rarely symptom-
atic.
In case of recurrent carotid stenosis, stent placement
is the method of choice according the criteria. In some
cases, carotid restenosis can also be treated by repeated
endarterectomy. The additional antiplatelet therapy (as-
pirin, clopidogrel) is essential, especially for the preven-
tion of thrombosis.
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TABLE 1
DISTRIBUTION OF RISK FACTORS AMOUNG THE STUDIED PATIENTS
Variable (N =178) CEA Restenosis p value
Number of patients 178 27
Mean age (years) 73.3 66.8
Sex
Male 102 12 0.2203
Female 76 15
Overweight (BMI) 103 9 0.0114
PAD 31 9 0.0671
Homocysteine level over 5 mmol/L (N=91) 49 19 0.1823
Stroke or TIA 139 4
 0.001
Current tobacco use 75 9 0.4110
Coronary artery desease 61 10 0.8294
Prior stent or surgical bypass graft mellitus 41 8 0.4173
Hypertension 152 23 1
Diabetes mellitus 81 14 0.543
Hyperlipidemia 97 17 0.5336
Chronic renal failure (creatinine >2) 24 4 0.7698
Atrial fibrilation 34 5 1
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RANA IDENTIFIKACIJA BOLESNIKA OD POVE]ANOG RIZIKA ZA RAZVOJ POSTOPERATIVNE
RESTENOZE KAROTIDNIH ARTERIJA
S A @ E T A K
Mnogobrojna randomizirana istra`ivanja posljednje desetlje}e simptomatskih i asimptomatskih karotidnih stenoza
dokazale su uspje{nost karotidne endarterektomija (KEA) u sni`avanju rizika za nastanak mo`danog udara. Cilj ove
prospektivne nerandomizirane kohortne studije bio je utvrditi incidenciju restenoze karotidnih arterija nakon karo-
tidne endarterektomija (KEA) te procijeniti klini~ke karakteristike i etiolo{ke ~imbenike za razvoj restenoze. Obra|eni
su podaci 178 bolesnika lije~enih u KBC Rijeka, kojima je u~injena KEA u razdoblju od 1. rujna 2005. do 30. kolovoza
2009. godine. Preoperativna obrada, klini~ko te ultrazvu~no postoperativno pra}enje u~injeno je pri Zavodu za cerebro-
vaskularne bolesti i Neurosonolo{kom laboratoriju Klinike za neurologiju KBC Rijeka. Svi bolesnici su pra}eni prema
algoritmu na{eg Neurosonolo{kog laboratorija – prvi ultrazvu~ni pregled u prvih tjedan dana nakon KEA te kontrolni
nakon 1, 3, 6 i 12 mjeseci. Nakon toga jednom godi{nje. Prosje~no vrijeme pra}enja bilo je 21 mjesec (3–36 mjeseci). U
navedenom periodu dijagosticirano je 27 restenoza (15,16%). Od svih restenoza samo su 4 bile simptomatske(14,81%).
Pre`ivljavanje pacijenta je 98 i 92% u 12 i 36 mjeseci. Karotidna restenoza naj~e{}e je asimptomatska. Postoperativno
neinvazivno ultrazvu~no pra}enje karotidnih arterija bitan je ~imbenik u ranoj identifikaciji pacijenata s rizikom za
razvoj restenoza.
